Lodge Partners has maintained its Buy rating for EZZ Life Science (ASX:EZZ), while increasing its price target from $0.84 to $1.00.
This new target price reflects a huge implied upside of 138% from current share price levels, with the upgrade coming as the broker updated its investment thesis on EZZ following a strong first half.
New Price Target of 1 $ by Lodge partners
Add EZZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
83.0¢ |
Change
-0.030(3.49%) |
Mkt cap ! $36.86M | |||
| Open | High | Low | Value | Volume |
| 84.5¢ | 84.5¢ | 82.5¢ | $78.40K | 94.50K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3471 | 82.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 83.0¢ | 13458 | 1 |
View Market Depth
| Last trade - 13.20pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
84.5¢ |
Change
-0.030 ( 1.17 %) |
||||
| Open | High | Low | Volume | ||
| 84.5¢ | 84.5¢ | 84.5¢ | 869 | ||
| Last updated 12.00pm 06/05/2024 ? | |||||
| EZZ (ASX) Chart |